LOGIN  |  REGISTER
Assertio
Assertio

Certara Appoints James E. Cashman III as Chairman of Board of Directors

November 08, 2021 | Last Trade: US$11.88 0.26 2.24

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that James E. Cashman III, a current Board member, will be appointed Chairman of the Board of Directors, effective as of December 1, 2021. Jim succeeds Sherilyn McCoy, who is stepping down from the Board to focus on other professional commitments.

"It has been a privilege to serve as Chairman of Certara’s Board of Directors, and I am proud of the Company’s strong performance and accomplishments," said Ms. McCoy. "Certara is well-positioned for continued success with an outstanding leadership team.”

“On behalf of the Board, I would like to thank Sheri for all of her contributions to Certara. We wish her all the best in her endeavors,” said William F. Feehery, Ph.D., CEO of Certara.  “I am excited to continue working with Jim as he assumes the role of Chairman. His proven track record at Ansys and passion for simulation-driven product development will help advance Certara’s innovation and global expansion.”

James E. Cashman III has been a board member at Certara since 2018. He served for 20 years in the CEO and Executive Chairman roles at ANSYS, Inc., the global leader of engineering simulation software. Under his leadership, Ansys grew from $50 million to over $1 billion in revenue and was one of the top five public technology companies in total shareholder returns.

“I am honored to serve as Chairman of Certara’s Board. I am inspired by Certara’s cutting-edge biosimulation technology and its impact on improving the drug development process and patient outcomes,” said James Cashman. “I look forward to working closely with the Board, William and the leadership team to create sustained value for all of Certara’s stakeholders.”

About Certara

Certara accelerates medicines using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Contacts:

Investor Relations
David Deuchler
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media
Daniel Yunger
Kekst CNC
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Ariane Lovell
Finn Partners
This email address is being protected from spambots. You need JavaScript enabled to view it. 


C4 Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page